PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
26108692-0	2015	Lithium chloride antileukemic activity in acute promyelocytic leukemia is GSK-3 and MEK/ERK dependent.	Lithium Chloride	0-16	midkine	Mus musculus	84-87	
26108692-2	2015	To target the MEK/ERK pathway, we identified glycogen synthase kinase-3beta (GSK-3beta) inhibitors including lithium chloride (LiCl) as activators of this pathway in APL cells.	Lithium Chloride	109-125	midkine	Mus musculus	14-17	
26108692-2	2015	To target the MEK/ERK pathway, we identified glycogen synthase kinase-3beta (GSK-3beta) inhibitors including lithium chloride (LiCl) as activators of this pathway in APL cells.	Lithium Chloride	127-131	midkine	Mus musculus	14-17	
26108692-7	2015	In this work, we demonstrate that LiCl, a well-tolerated agent in humans, has antileukemic activity in APL and that it has the potential to restore RA-induced transcriptional activation and differentiation in RA-resistant APL cells in an MEK/ERK-dependent manner.	Lithium Chloride	34-38	midkine	Mus musculus	238-241	
23904208-0	2014	Lithium chloride induces TNFalpha in mouse macrophages via MEK-ERK-dependent pathway.	Lithium Chloride	0-16	midkine	Mus musculus	59-62